Hospitalised ischaemic cerebrovascular accident and risk factors in a primary care database

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 10, 2011, Pages 1050-1056

  Martín Merino, Elisa ^a   Ruigomez, Ana ^a   Johansson, Saga ^b,c   García Rodríguez, Luis Alberto ^a  

^a Spanish Centre for Pharmacoepidemiologic Research ^*  (Spain)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrovascular disease; Epidemiology; Primary care; Risk factors

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DATA BASE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC CEREBROVASCULAR ACCIDENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SEX RATIO; SMOKING; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS; SEX FACTORS; SMOKING; STROKE;

EID: 80053274377     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2201     Document Type: Article

References (32)

1. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-344.
2. Gibbs RG, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001; 32: 1085-1090.
3. Kuller LH. Epidemiology and prevention of stroke, now and in the future. Epidemiol Rev 2000; 22: 14-17.
4. Morley J, Marinchak R, Rials SJ, Kowey P. Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 1996; 77: 38A-44A.
5. Giampaoli S, Palmieri L, Panico S et al. Favorable cardiovascular risk profile (low risk) and 10-year stroke incidence in women and men: findings from 12 Italian population samples. Am J Epidemiol 2006; 163: 893-902.
6. Remmel KS, Wanahita A, Moore K, Gruenthal M. Acute ischemic stroke and hypothyroidism. J Ky Med Assoc 2006; 104: 191-193.
7. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-892.
8. Gubitz G, Sandercock P. Prevention of ischaemic stroke. BMJ 2000; 321: 1455-1459.
9. Wolfe CD, Rudd AG, Howard R et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2002; 72: 211-216.
10. Rothwell PM, Coull AJ, Giles MF et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-1933.
11. Truelsen T, Piechowski-Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13: 581-598.
12. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 1995; 26: 361-367.
13. Liebetrau M, Steen B, Skoog I. Stroke in 85-year-olds: prevalence, incidence, risk factors, and relation to mortality and dementia. Stroke 2003; 34: 2617-2622.
14. Rothwell PM. Incidence, risk factors and prognosis of stroke and TIA: the need for high-quality, large-scale epidemiological studies and meta-analyses. Cerebrovasc Dis 2003; 16(Suppl 3): 2-10.
15. Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf 2010; 19: 579-585.
16. Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517-584.
17. Sciolla R, Ferrari G, Leone M. Stroke and transient ischaemic attack in 18 neurology departments from two Italian Regions: the SINPAC database. Neurol Sci 2005; 26: 208-217.
18. Liu XF, van Melle G, Bogousslavsky J. Analysis of risk factors in 3901 patients with stroke. Chin Med Sci J 2005; 20: 35-39.
19. Whisnant JP, Wiebers DO, O'Fallon WM, Sicks JD, Frye RL. A population-based model of risk factors for ischemic stroke: Rochester, Minnesota. Neurology 1996; 47: 1420-1428.
20. Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 2003; 34: 2050-2059.
21. Ghandehari K, Izadi-Mood Z. Khorasan stroke registry: analysis of 1392 stroke patients. Arch Iran Med 2007; 10: 327-334.
22. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
23. Hart RG, Halperin JL. Atrial fibrillation and stroke:concepts and controversies. Stroke 2001; 32: 803-808.
24. Pengo V, Zasso A, Barbero F et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998; 82: 433-437.
25. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.
26. Neligan A, Shorvon SD. Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol 2010; 67: 931-940.
27. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128: 89-95.
28. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
29. Esper RJ, Machado R, Vilarino J et al. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. Am Heart J 2000; 140: 684-689.
30. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109: II34-II41.
31. Ntaios G, Savopoulos C, Chatzopoulos S, Mikhailidis D, Hatzitolios A. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis. Atherosclerosis 2011; 214(1): 11-19.
32. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.